Related by context. All words. (Click for frequent words.) 67 ENMD # 67 antiangiogenic agents 67 multitargeted 67 antitumor efficacy 67 effector function 66 favorable tolerability 66 ganetespib 66 R roscovitine 66 TO AVOID PREGNANCY WHILE 66 Taxotere chemotherapy 66 FOLFOX6 65 paclitaxel Taxol ® 65 demonstrated antitumor activity 65 MEK inhibitors 65 Pazopanib 65 anti leukemic 65 antitumor activity 65 tolerability profiles 65 kinase inhibition 65 Bezielle 65 Antitumor Activity 65 CYT# potent vascular disrupting 65 anticancer activity 65 Archexin 65 delafloxacin 65 xenograft models 65 mTOR inhibitors 65 NEUGENE 65 thalidomide Thalomid 64 pharmacodynamic properties 64 antitumor effects 64 overlapping toxicities 64 Panzem R NCD 64 efficacy tolerability 64 Hormone Refractory Prostate Cancer 64 trastuzumab Herceptin ® 64 K ras mutations 64 MAGE A3 ASCI 64 immune modulating 64 dasatinib Sprycel 64 teriflunomide 64 Exelixis compounds 64 vascular disrupting agents 64 receptor tyrosine kinase inhibitor 64 Pertuzumab 64 melphalan prednisone 64 FUSILEV enhances 64 Darinaparsin 64 liposomal formulation 64 antiviral efficacy 64 BRAF inhibitor 64 Carfilzomib 64 liposome formulation 64 HCV protease inhibitors 64 delta isoform 64 immunomodulatory therapy 63 CCX# 63 liposomal amphotericin B 63 proteasome inhibitors 63 Virulizin ® 63 antiangiogenic activity 63 Q#IR 63 vidofludimus 63 histone deacetylase inhibitor 63 paclitaxel Taxol 63 Doxil ® 63 gemcitabine Gemzar 63 relapsed SCLC 63 cisplatin gemcitabine 63 5 FU leucovorin 63 oral anticancer 63 PEGylated interferon 63 oral prodrug 63 metaglidasen 63 Aurora Kinase 63 cytoprotective 63 Pemetrexed 63 XP# XP# 63 pegylated interferons 63 docetaxel Taxotere ® 63 Vidaza azacitidine 63 Cethrin R 63 selective modulator 63 adenosine injection 63 Intravenous CP 63 clevidipine 63 erlotinib Tarceva ® 63 CG# [003] 63 anti angiogenic agents 63 galiximab 63 orally administered inhibitor 63 pharmacokinetic profiles 63 pharmacodynamics PD 63 DACH platinum 63 DexaSite 63 FOLFOX6 chemotherapy regimen 63 Combination therapy 63 LEP ETU 63 dosage regimens 63 gemcitabine Gemzar ® 63 Traficet EN 63 pharmacokinetic interactions 63 uric acid lowering 63 antiangiogenic agent 63 Alequel 62 novel emulsion formulation 62 paclitaxel cisplatin 62 Romidepsin 62 LHRH antagonists 62 small molecule tyrosine 62 PEG SN# 62 alfa 2a 62 Blinatumomab 62 refractory chronic lymphocytic 62 Interferon beta 62 Fludarabine 62 antianginal 62 tyrosine kinase inhibitor TKI 62 ritonavir boosted 62 nucleoside analog 62 CIMZIA ™ 62 TLR8 agonist 62 alpha 2a 62 Peginterferon alfa 2b 62 antimitotic 62 Natalizumab 62 adalimumab Humira 62 oxidative stress inducer 62 novel VDA molecule 62 antiangiogenesis 62 corticosteroid dexamethasone 62 proteasome inhibitor 62 Erlotinib 62 sorafenib tablets 62 potency selectivity 62 relapsed MM 62 HGS ETR2 62 tanespimycin 62 sorafenib Nexavar 62 anti angiogenic agent 62 RhuDex TM 62 Aplidin 62 relapsed ovarian cancer 62 lintuzumab SGN 62 virologic responses 62 microtubule targeting 62 Pegylated Interferon 62 VEGF receptor inhibitor 62 chemotherapy hormonal therapy 62 CTAP# Capsules 62 SCH # 62 investigational humanized monoclonal antibody 62 AAG geldanamycin analog 62 posaconazole 62 mapatumumab 62 pomalidomide 62 PRT# 62 IMC A# 62 Kinoid 62 Tumor Response 62 systemically administered 62 urate lowering 62 MyVax R 62 SUTENT ® 62 Cardiotoxicity 62 alvespimycin 62 lenalidomide dexamethasone 62 anti amnesic 62 docetaxel Taxotere 62 antiresorptive 62 enzastaurin 62 tigecycline 62 mertansine 62 concurrent chemoradiation 62 Akt activation 62 gemcitabine cisplatin 62 reversible inhibitor 62 potent antiproliferative 62 riociguat 62 PNP inhibitor 62 Anticalin R 61 Vidofludimus 61 platelet inhibitor 61 liposomal doxorubicin 61 LymphoStat B belimumab 61 CIMZIA TM certolizumab pegol 61 generation purine nucleoside 61 Golimumab 61 HuMax EGFr 61 Pharmacokinetics PK 61 Apoptone 61 Fulvestrant 61 Xelox 61 IFN α 61 HDAC Inhibitor 61 briakinumab 61 cannabinor 61 pharmacodynamic profile 61 sunitinib malate 61 cediranib 61 PEGylated interferon beta 1a 61 HQK 61 intranasal delivery 61 Interferon alpha 61 multi kinase inhibitor 61 selective kinase inhibitor 61 HGS ETR1 mapatumumab 61 viral kinetics 61 Tyrima 61 tumor xenograft models 61 Preclinical studies suggest 61 Aflibercept 61 doxorubicin cyclophosphamide 61 vinca alkaloid 61 Panzem R 61 albumin bound paclitaxel 61 orally dosed 61 BAL# [002] 61 synthase TS 61 pharmacokinetic properties 61 Albuferon TM 61 ribavirin therapy 61 fluoropyrimidine 61 pertuzumab 61 IAP inhibitor 61 MetMAb 61 mycophenolate mofetil 61 Hedgehog inhibitor 61 EndoTAGTM 1 61 antithrombotic 61 apremilast 61 Immunomodulatory 61 PSMA ADC 61 PI3K/mTOR 61 NEUGENE antisense 61 M# rationally 61 favorable pharmacokinetic profile 61 JAK inhibitors 61 pan HDAC inhibitor 61 mTOR kinase 61 ® bortezomib 61 surgical debulking 61 FOLPI 61 Thiovir 61 KRN# 61 DAVANAT 61 Seliciclib 61 radiation sensitizer 61 HER2 ErbB2 61 AKT inhibitor 61 paclitaxel poliglumex 61 RNA antagonist 61 Janus Kinase 61 HMG CoA reductase inhibitors 61 vivo potency 61 Xanafide 61 humanised monoclonal antibody 61 mTOR inhibition 61 fibrinolytic 61 TroVax ® 61 Campath alemtuzumab 61 Xeloda ® 61 Vaxfectin R 61 Glufosfamide 61 APTIVUS R 61 Panzem NCD 61 zoledronate 61 Antiviral Activity 61 potent antitumor activity 61 pegylated liposomal doxorubicin 61 mecamylamine 61 EGFR HER2 61 Anticalin ® 61 alkylating agent 61 induce remission 61 TPI ASM8 61 GMX# 61 intra arterial chemotherapy 61 OMP #M# 61 targeted antifolate 61 XL# XL# XL# XL# 61 targeting CD# 61 YONDELIS 61 Tasimelteon 61 XL# anticancer compounds 61 estramustine 61 R lenalidomide 61 Platinol ® cisplatin 61 personalized immunotherapy 61 DCVax R 61 PEGylated Fab fragment 61 pegylated IFN 61 Hsp# inhibition 60 Mg Uk 60 EGFR antibodies 60 Fludara ® 60 selective inhibition 60 Trastuzumab 60 neratinib 60 evaluating tivozanib 60 dacetuzumab 60 lumiliximab 60 Irinotecan 60 CorVue ™ 60 Disease Progression 60 erlotinib Tarceva 60 PegIFN 60 antiangiogenic therapy 60 IMA# 60 heavily pretreated patients 60 coadministration 60 milatuzumab 60 ixabepilone 60 PI3K inhibitors 60 Zoraxel 60 CYP#A# CYP#D# 60 Triapine R 60 JAK2 inhibitors 60 angiogenesis inhibition 60 Allovectin 7 ® 60 Epidermal Growth Factor Receptor 60 partial agonist 60 limiting toxicity DLT 60 XL# XL# 60 boosted protease inhibitor 60 chemopreventive agents 60 Anidulafungin 60 TLR antagonists 60 IMiDs ® 60 Symadex 60 MTP inhibitor 60 TELINTRA 60 Peginterferon Alfa 2b 60 prokinetic agent 60 HGS# 60 idarubicin 60 depsipeptide 60 temsirolimus 60 IRX 2 60 intravenous cyclophosphamide 60 SPRYCEL ® 60 maximally tolerated lipid lowering 60 Octreolin 60 JAK2 inhibitor 60 target enzyme thymidylate 60 signal transduction inhibitor 60 Omacetaxine 60 DEB# 60 small molecule thrombopoietin 60 Anthracycline 60 Adefovir 60 peptide conjugated 60 Nilotinib 60 factor TNF 60 paclitaxel Taxol R 60 Evoltra ® 60 Tarceva TM 60 anthracycline containing 60 PI3K/Akt pathway inhibitor 60 Tolerability 60 antidepressant efficacy 60 nab paclitaxel 60 OvaRex R 60 plasma kallikrein inhibitor 60 preclinically 60 hypereosinophilic syndrome 60 nebulized formoterol fumarate 60 hematological parameters 60 dasatinib Sprycel ® 60 HERCEPTIN 60 ara C 60 LHRH receptor positive 60 Aplidin R 60 pathophysiological effects 60 cetuximab Erbitux R 60 capecitabine Xeloda 60 antitumor effect 60 OncoVEX GM CSF 60 Insulin detemir 60 Mitoxantrone 60 chemotherapy FOLFOX 60 MEK Inhibitor 60 TLR9 agonist 60 interferon IFN 60 immunomodulation 60 endocrine therapies 60 ON #.Na 60 indibulin 60 Synta Announces 60 accumulate preferentially 60 imatinib Gleevec ® 60 immunotherapeutic approaches 60 cetuximab Erbitux ® 60 CA4P 60 TRPV1 agonist 60 PEGylated anti 60 oral picoplatin 60 liposome encapsulated 60 Hsp# Inhibitor 60 Enzastaurin 60 Linjeta TM 60 radiochemotherapy 60 mTOR inhibitor 60 HuLuc# 60 Xeloda capecitabine 60 Presents Preclinical Data 60 Vidaza ® 60 VDAs 60 RGB # 60 pharmacodynamic PD 60 oral bioavailability 60 durable remissions 60 investigational monoclonal antibody 60 CYP#A# substrate 60 Targretin 60 bevacizumab Avastin Genentech 60 radiotherapy RT 60 sunitinib Sutent 60 PXD# 60 adecatumumab 60 BrachySil TM 60 PDE4 inhibitors 60 Annamycin 60 Valdoxan 60 Mg Usa 60 TNF Tumor Necrosis Factor 60 Pegylated interferon 60 CCR9 antagonist 60 cMET 60 interferon alfa 2b 60 novel anticancer 60 Perifosine 60 dexamethasone Decadron 60 chemopreventive agent 60 sapacitabine CYC# 60 myopathy rhabdomyolysis 60 ibandronate 60 p# inhibitor 60 intravenous dosing 60 Ambrisentan 60 CYC# 60 samalizumab 60 drug zotarolimus 60 beta interferons 60 KRAS status 60 dosing frequency 60 taxane chemotherapy 60 sunitinib Sutent ® 60 ribavirin USP 60 orally inhaled migraine 60 Tumor Necrosis Factor 60 oral diclofenac 60 5FU 60 antiangiogenesis therapies 60 erythropoietic 60 RH1 59 Interferon beta 1a 59 ChronVac C R 59 haematologic 59 forodesine 59 Budesonide foam crofelemer 59 tipranavir 59 oral rivaroxaban 59 dose proportionality 59 cytotoxic effects 59 Dapagliflozin 59 antitumor 59 daunorubicin 59 GRN#L 59 BZL# 59 interferon ribavirin 59 Dose Escalation 59 imatinib Gleevec 59 potentially hepatotoxic 59 IMiDs R 59 leukotriene receptor antagonist 59 pharmacokinetic equivalence 59 Gleevec resistant 59 neovascular diseases 59 ruxolitinib 59 Anticalins R 59 CCR5 antagonist 59 reactogenicity 59 proteins peptides 59 pain palliation 59 TRIOLEX HE# APOPTONE HE# 59 DermaVir Patch 59 hepatotoxic 59 colorectal liver metastases 59 panitumumab Vectibix 59 sarcoma melanoma 59 Chemokine Receptor 59 immune dysregulation 59 binding affinity 59 Prostacyclin 59 LHRH agonists 59 renal toxicity 59 maximally tolerated dose 59 Carvedilol 59 Locked Nucleic Acid LNA 59 histone deacetylase HDAC inhibitor 59 essential thrombocythemia ET 59 antisense inhibitors 59 Azedra 59 obatoclax 59 peptibody 59 conventional DMARDs 59 Adenoscan 59 metastatic RCC 59 aspirin clopidogrel 59 elacytarabine 59 Patients Treated With 59 inhibit platelet function 59 fusion enhancers 59 fluticasone salmeterol 59 JAK inhibitor 59 APOPTONE 59 MGN# 59 EXPAREL ™ 59 Gemcitabine 59 Novel Oral 59 Bosutinib 59 #HT#A 59 immunostimulatory 59 KSP inhibitor 59 SYN# 59 Interferon Beta 59 histologies 59 analgesic efficacy 59 insulin sensitizing 59 temsirolimus Torisel ® 59 torsemide ER 59 Anticalins ® 59 LT NS# 59 Aurora kinase 59 antihormonal 59 Bortezomib 59 CIMZIA TM 59 pharmacodynamic markers 59 ZD# [001] 59 potently inhibit 59 thienopyridine 59 GnRH antagonist 59 TNF alpha antagonist 59 GW# [003] 59 seliciclib 59 APTIVUS 59 MET amplification 59 S/GSK# 59 TG# [001] 59 immunomodulating 59 chemotherapy docetaxel 59 tolerability profile 59 ZOLINZA 59 Denufosol 59 bendamustine 59 Tyrosine Kinase Inhibitor 59 Aptivus ® 59 intracellular uptake 59 Antiangiogenic 59 genotypic resistance 59 INCB# [001] 59 gefitinib Iressa 59 pegylated interferon alfa 59 CRLX# 59 Capecitabine 59 Zoraxel TM 59 antiplatelet 59 PegIFN RBV 59 R Saizen R 59 Etoposide 59 BiTE 59 immunomodulatory agents 59 dosing regimens 59 romidepsin 59 Oral NKTR 59 RAS MAPK pathway 59 lenalidomide Revlimid R 59 pramlintide metreleptin combination 59 ProSavin 59 Kinase Inhibitor 59 radezolid 59 bacillus Calmette Guerin 59 Anti Tumor Activity 59 hematological toxicity 59 TNF α 59 3D conformal radiation 59 immunosuppressive regimen 59 calcineurin inhibitors 59 glycosylation profile 59 5 HT2A serotonin 59 pharmacodynamic parameters 59 triciribine phosphate monohydrate 59 efficacy 59 echinocandin 59 novel nucleoside analog 59 axitinib 59 nonclinical studies 59 BRAF inhibitors 59 oxymorphone ER 59 TLR9 agonists 59 biodistribution 59 humanized therapeutic 59 antidiabetic drugs 59 favorable pharmacokinetic 59 novel histone deacetylase 59 VAPRISOL 59 Fondaparinux 59 interferon alfa 59 AEGR 59 volociximab 59 nicardipine 59 pharmacodynamic effects 59 Vandetanib 59 antiemetic 59 #D#C# 59 ALK inhibitor 59 antiapoptotic 59 BEXXAR Therapeutic Regimen 59 Akt inhibitor 59 PEGPH# 59 metastatic CRC 59 TAFA# 59 VELCADE melphalan 59 Camptosar ® 59 Geron telomerase inhibitor 59 oral clodronate 59 CYT# 59 otelixizumab 59 Vicinium TM 59 Dasatinib 59 Immunotherapeutic 59 AIR# [001] 59 Aliskiren 59 cardiac contractility 59 EGFR tyrosine kinase inhibitors 59 receptor inhibitor 59 RoACTEMRA 59 Complicated Skin 59 TNF inhibitor 59 ceftazidime 59 eprotirome 59 null responder 59 tipifarnib 59 gastrointestinal stromal tumors GIST 59 debulking surgery 59 dopamine partial agonist 59 Hsp# inhibitors 59 microtubule inhibitor 59 oral ridaforolimus 59 SERMs 59 pyridostigmine 59 Ocrelizumab 59 reduce serum phosphate 59 antiproliferative 59 temozolomide TMZ 59 Cytotoxic 59 dimebon latrepirdine 59 bortezomib Velcade 59 5 HT3 antagonist 59 Lubiprostone 59 tamoxifen Nolvadex ® 59 Zemplar Capsules 59 thetreatment 59 Transmembrane 59 endothelin receptor antagonists 59 MGd 59 bexarotene 59 targeted radiotherapeutic 59 elotuzumab 59 treating neuropathic pain 59 motesanib 59 RhuDex ® 59 Abatacept 59 rxRNA 59 adefovir dipivoxil 59 oral antiplatelet 59 standard chemotherapy regimens 59 Adjuvant Treatment 59 metastatic neuroendocrine tumors 59 epigenetic therapies 59 intravesical 59 oral antiviral 59 CCX# B 59 hypofractionated 59 Perforomist ™ Inhalation Solution 59 HSP# inhibitor 59 anthracyclines taxanes 59 taxane chemotherapy administered 59 flavopiridol 59 Myelofibrosis 59 oral renin inhibitor 59 tumor histology 59 maximally tolerated 59 vascular disrupting agent 59 antithrombotics 59 STELARA ® 59 molecular biomarkers 59 etoposide 59 Delta opioid receptor 58 postoperative chemotherapy 58 nucleotide analogs 58 busulfan 58 NMDA antagonists 58 Solorel TM 58 Tezampanel 58 immune modulatory 58 V#F mutation 58 anti CD# antibodies 58 interferon therapy 58 Novartis Gleevec 58 K RAS 58 ACTEMRA TM 58 LHRH analogues 58 sustained virological response 58 Solazed 58 direct thrombin inhibitors 58 RezularTM 58 Gefitinib 58 DCCR 58 metastatic malignant 58 Pruvel 58 CaPre TM 58 ocular formulation 58 preclinical efficacy 58 cytotoxic agents 58 Peginterferon 58 basal insulin analogue 58 GLYX 58 AVASTIN 58 CD8 + cytotoxic 58 dipyridamole 58 Castration Resistant Prostate Cancer 58 pharmacokinetic characteristics 58 lymphomas leukemias 58 antiarrhythmic 58 leukemia multiple myeloma 58 lipid lowering therapies 58 DAPT 58 Amplimexon 58 Demonstrates Significant 58 hypoxia activated prodrug 58 Combo Stent 58 sipuleucel T 58 octreotide acetate 58 Epothilones 58 bezafibrate 58 Diovan HCT 58 AEG# 58 Gastrointestinal Stromal Tumors 58 ulimorelin 58 tumor antigen 58 liver metastasis 58 Lisofylline 58 INC# 58 HCD# [002] 58 Amrubicin 58 oral JAK1 58 XL# SAR# 58 Toxicities 58 recombinant interferon 58 myelofibrosis polycythemia vera 58 etanercept Enbrel 58 TKM ApoB 58 dose proportional pharmacokinetics 58 bevacizumab Avastin ® 58 Crofelemer budesonide foam 58 prescribed proton pump 58 IFN gamma 58 Combination REOLYSIN R 58 antisense compounds 58 EGFR inhibitors 58 fulvestrant 58 decitabine 58 Hematologic toxicity 58 Rigel R# 58 oral talactoferrin 58 Temsirolimus 58 demethylating agent 58 antifungal therapy 58 Pralatrexate 58 anti miRs 58 heparanase 58 nonnucleoside reverse transcriptase inhibitors 58 OXIGON TM 58 noninfectious uveitis 58 Sudhir Agrawal D.Phil 58 trastuzumab Herceptin 58 veltuzumab 58 Taxol paclitaxel 58 Surgical resection 58 reverse transcriptase inhibitors 58 cytotoxic chemotherapy 58 TEMODAL 58 A3 adenosine receptor 58 Refractory Hodgkin Lymphoma 58 angiogenesis inhibitor 58 TG# [003] 58 Safinamide 58 Talabostat 58 visilizumab 58 topical gel formulation 58 prospectively stratified 58 follicular lymphoma FL 58 DOS# 58 neurotrophic 58 Amgen Neulasta R 58 REMINYL ® 58 tumor regressions 58 LibiGel ® 58 cardiac toxicity 58 cidofovir 58 mGluR5 antagonists 58 intravenous recombinant 58 investigational therapies 58 Sorafenib 58 ARIKACE ™ 58 mg/m2 dose 58 non selective NSAIDs 58 LEVAQUIN ® 58 chimeric monoclonal antibody 58 Cloretazine 58 Inhaled nitric oxide 58 IFN beta 58 Tarvacin TM 58 c MYC 58 Enhanze Technology 58 Panzem 58 dose cohort 58 INVEGA ® 58 Simulect 58 Decitabine 58 BAL# [001] 58 APTIVUS r 58 interferon alpha IFN 58 beta lactamase inhibitor 58 Alfacell proprietary ribonuclease 58 platelet inhibition 58 EGFR TKI 58 Pegasys peginterferon alfa 2a 58 budesonide foam 58 Pharmacokinetic studies 58 refractory metastatic 58 PCK# 58 ALGRX 58 oral immunomodulatory 58 Neulasta ® 58 myeloproliferative diseases 58 Reports Preclinical Data 58 vivo efficacy 58 oral Xeloda 58 amifostine 58 Elitek 58 plus prednisone prednisolone 58 interferon gamma 1b 58 vapreotide acetate 58 lintuzumab 58 trastuzumab Herceptin R 58 Protein Kinase C 58 recombinant erythropoietin 58 antiemetics 58 TRX1 58 immunomodulators 58 immunoconjugate 58 interferon alfa 2a 58 brand ciclesonide HFA 58 eTag assays 58 REP# 58 Navelbine ® 58 Pegasys ® 58 virological response 58 ESBA# 58 VEGF inhibitors 58 potent anticancer 58 fibrinolysis 58 CEQ# 58 Vascugel ® 58 Taxol ® 58 intravenously administered 58 nephrotoxicity 58 Modrenal 58 Preclinical Data 58 pyrazinamide 58 tumor hypoxia 58 BYETTA exenatide injection 58 HIF PHI 58 Targretin capsules 58 severe hypersensitivity reactions 58 Anti Tumor 58 intravascular hemolysis 58 ELACYT 58 Quinamed 58 convenient dosing regimen 58 Estrogen Receptor 58 Tasigna prolongs 58 TLR agonists 58 intravesical instillation 58 fluconazole resistant 58 idraparinux 58 Metastatic Renal Cell Carcinoma 58 M1 muscarinic 58 administered subcutaneously 58 non squamous histology 58 molecularly targeted 58 Naive Patients 58 Spiegelmer ® 58 HDAC inhibition 58 Factor Xa inhibitor 58 Vitaxin 58 hematological indications 58 Afatinib 58 fosbretabulin 58 regorafenib 58 Chronic HCV 58 receiving immunosuppressive therapy 58 IMC #B 58 immunomodulatory 58 OXi# 58 Everolimus 58 adjuvant therapies 58 novel peptide 58 micafungin 58 antiandrogens 58 resistant hormone refractory 58 Sym# 58 FEMALES SHOULD BE ADVISED 58 dose cyclophosphamide 58 pharmacodynamic profiles 58 inhibit replication 58 Phase 1b clinical trials 58 cellular uptake 58 SGLT 2 58 PDE4 inhibitor 58 MDS AML 58 antimetabolite 58 Demonstrates Potential 58 BNC# 58 TNF alpha inhibitor 58 fluoroquinolone antibiotic 58 tolerability 58 PKC# 58 adriamycin 58 Pimavanserin 58 carboplatin paclitaxel 58 Revlimid lenalidomide 58 peptide antigens 58 Cytarabine 58 Pegloticase 58 conventional chemotherapies 58 Interferon Alpha 58 kinase inhibitor 58 PPARg 58 oncologic outcomes 58 ISF# 58 TRAIL induced apoptosis 58 RLY# 58 subcutaneous dosing 58 immunomodulator 58 Telik logo TELINTRA 58 mouse xenograft models 58 immunological responses 58 signal transduction inhibitors 58 CBLC# 58 aldosterone antagonists 58 neoadjuvant treatment 58 ovarian suppression 58 oral FTY# 58 Nanobody 58 chronic eosinophilic leukemia 58 resolvins 58 Rebif ® 58 d l leucovorin 58 torezolid phosphate 58 anthracycline taxane 58 iclaprim 58 Lorianne Masuoka MD 58 TRAIL receptor antibodies 58 Oral Fingolimod 58 MoxDuo 58 Prolongs Survival 58 systemic absorption 58 MGCD# [001] 58 Vildagliptin 58 peptidomimetic 57 pro apoptotic 57 baminercept 57 tolterodine 57 Renal Cell Carcinoma 57 Tanespimycin 57 amrubicin 57 PORxin TM 57 morphometric vertebral fractures 57 Meets Primary Endpoint 57 Peginterferon Alfa 2a 57 recurrent glioblastoma 57 5 fluorouracil leucovorin 57 TriRima 57 Roche Chugai s 57 alefacept